A Randomized Double-blind Placebo-controlled Multicenter Study to Evaluate the Safety Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy

Brief description of study

This is a research study to evaluate the safety, tolerability and effectiveness of the study drug XEN1101 for reducing the frequency of focal seizures in patients when taken daily with your other antiepileptic drugs.The purpose of this study is to evaluate the safety, tolerability and effectiveness of an experimental drug called XEN1101 in reducing the frequency of focal seizures in subjects when taken daily with other anti-epileptic drugs. An experimental drug is one that is being tested and is not approved by the United States Food and Drug Administration (FDA). This drug has been tested in healthy volunteers but this is the first time it will be tested in subjects with focal-onset epilepsy.


Clinical Study Identifier: s18-01458
ClinicalTrials.gov Identifier: NCT03796962
Principal Investigator: Claude Steriade
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.